Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT RCC: intensified pharmacology monitoring of cabozantinib for toxicity management in renal cell carcinoma
2026-525267-40-00Phase 4Authorised
- Sponsor
- Centro di Riferimento Oncologico di Aviano
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of cabozantinib and nivolumab in renal cell carcinoma (RCC) (2 arms), sponsored by Centro di Riferimento Oncologico di Aviano. Primary endpoint: Reduction in toxicity-related treatment interruptions. Planned start May 2026; status: authorised.
02
Drugs
cabozantinibnivolumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2026-525267-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525267-40-00.